Form 4: Quest Diagnostics Executive Mark Delaney Reports Stock Transactions

Mark Delaney, SVP & Chief Commercial Officer of Quest Diagnostics, reports the acquisition and disposal of company stock.

Summary

• On July 22, 2024, Mark Delaney acquired 6 shares of Quest Diagnostics common stock at a price of $146.984 per share through a dividend reinvestment plan.
• On July 24, 2024, Mark Delaney disposed of 420 shares of Quest Diagnostics common stock at a price of $143.08 per share.
• Following these transactions, Delaney beneficially owns 5,019 shares of Quest Diagnostics common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it simply reports stock transactions. The transactions themselves don't necessarily indicate a positive or negative outlook.

Positives

• The acquisition of shares through a dividend reinvestment plan indicates confidence in the company's future.

Negatives

• The disposal of 420 shares could be interpreted negatively, although it's a relatively small portion of Delaney's holdings.

Risks

• Executive stock transactions can sometimes be interpreted as a signal of the company's future performance, although this transaction appears routine.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies and are subject to regulatory oversight to prevent insider trading.

Stakeholder Impact

• The transactions may have a minor impact on shareholder sentiment, depending on how they are interpreted.

Key Dates